POLIDOCANOL VS STS FOR SPIDER VEINS. Steven E. Zimmet, MD RPVI RVT FACPh
|
|
- Meagan Cooper
- 6 years ago
- Views:
Transcription
1 POLIDOCANOL VS STS FOR SPIDER VEINS Steven E. Zimmet, MD RPVI RVT FACPh
2 Disclosures/COI No COI Off-label use
3 Lipid bilayer with membrane proteins Lipid bilayers are the basic structures that make up cell membranes. Membrane phospholipids are amphiphilic and contain a hydrophilic polar head group and a hydrophobic tail group.
4 Mechanism of Action Detergent sclerosants produce endothelial damage via interference with cell surface lipids Strong detergents, such as STS, produce maceration of the endothelium within 1 second of exposure. The intercellular cement is disrupted Detergent destructive action on endothelial cells is enhanced when they act as aggregates rather than monomers.
5 Bioactive Aggregates Critical Micellar Concentration Concentration dependent CMC of STS to be 0.075% in normal saline and 0.200% in water 1 CMC of POL to be 0.002% in both normal saline and water 1
6 Thus, the concentration of the sclerosing solution in the vessel is an important factor regarding endothelial destruction and activity
7 STS and POL are clinically used to induce endovascular fibrosis and vessel occlusion. They achieve this by lysing the endothelial lining of target vessels. These agents are surface active (surfactant) molecules that interfere with cell membranes. The ionic charge of the surfactant molecule can influence the effect on plasma proteins and the protein contents of cell membranes. STS, an anionic detergent, denatures the tertiary complex of most proteins and in particular the clinically relevant clotting factors. By contrast, POL has no effect on proteins due to its nonionic structure. These agents therefore exhibit remarkable differences in their interaction with lipid membranes, target cells and circulating proteins with potential implications in a range of clinical applications
8 Cell lysis reached almost 100 % with STS at 0.3 % and with POL at 0.6 %. Both sclerosants induced endothelial cell (EC) apoptosis at sub-lytic concentrations through a caspase-dependant pathway. Both agents induced EC oncosis. Cooley-Andrade et al. Apoptosis Jul;21(7):
9 The lytic effect of sclerosants is not limited to EC. Our group demonstrated lysis of erythrocytes, leukocytes, and platelets at concentrations specific to cell types Both sclerosants induced leukocyte apoptosis at sublytic concentrations. STS activated both extrinsic and intrinsic pathways of apoptosis, while POL stimulated the intrinsic pathway of apoptosis only. Both agents induced oncosis. Based on these results, STS appears to have a greater effect than POL. Cooley-Andrade et al. Eur J Vasc Endovasc Surg Jun;51(6):846-56
10 Histological Study 40 patients after spider vein ( mm diameter) treatment Punch biopsies obtained 15 minutes after treatment H&E stains Pre- and post-tx photos compared by authors regarding amount of intraluminal thrombus and hyperpigmentation Histological findings Level 1: endothelial cell destruction Level 2: subintimal disruption Level 3: fibrin replacement of vessel wall Level 4: disruption of vessel wall Bush et al. Evaluation of sodium tetradecyl sulfate and polidocanol as sclerosants for legtelangiectasia based on histological evaluation with clinical correlation. Accepted for publication in Phlebology
11 Histological Study
12 Histological Study Based on the histological determinations in this study, STS 0.15% and POL 0.31% appear to be equivalent in cellular alterations. The clinical effects after treatment with these two sclerosants are also similar with minimal staining and mild intraluminal thrombosis. Using concentrations less than the STS 0.15% or POL 0.31% is not as effective in producing the desired level of cellular damage. Using concentrations above these levels may produce thrombosis of vessel with resultant inflammatory changes and hyperpigmentation.
13 Sodium Tetradecyl Sulfate (STS) Anionic surfactant Nonmutagenic when tested in a mouse lymphoma assay, but no long-term animal carcinogenicity studies have been performed FDA-approved 1946 Commercially available preparations as1% or 3% solutions Indicated in the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves Sotradecol should be given to a pregnant woman only if clearly needed and the benefits outweigh the risks It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Sotradecol is administered to a nursing woman. Maximum single treatment should not exceed 10 ml. Can be readily made into foam (physician-compounded)
14 Polidocanol (POL) Non-ionic detergent, consisting of two components, a polar hydrophilic (dodecyl alcohol) and an apolar hydrophobic (polyethylene oxide) chain. FDA-approved 2010 Asclera (polidocanol) indicated to treat uncomplicated spider veins (varicose veins 1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. It has not been studied in larger varicose veins > 3 mm in diameter. Maximum 10 ml/session Severe allergic reactions have been reported following polidocanol use, including anaphylactic reactions, some of them fatal. Severe reactions are more frequent with use of larger volumes (> 3 ml). The dose of polidocanol should therefore be minimized. Be prepared to treat anaphylaxis appropriately. It is not known whether polidocanol is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, avoid administering to a nursing woman. Can readily made into foam (physician-compounded), commericially available as Varithena (GSV)
15 Clinical Pharmacology Mechanism of Action Damages endothelium Dense network of platelets, cellular debris and fibrin occludes the vein Pharmacodynamics Concentration and volume-dependent Pharmacokinetics The mean plasma half life (4 subjects) who received 4.5 to 18.0 mg polidocanol was 1.5 hours. These are far greater mg dosages than would be reached in a typical clinical setting. Maximum recommended volume per treatment session of 10 ml.
16 Polidocanol has been shown to have an embryocidal effect in rabbits when given in doses approximately equal (on the basis of body surface area) to the human dose. This effect may have been secondary to maternal toxicity. There are no adequate and wellcontrolled studies in pregnant women. Asclera should not be used during pregnancy.
17 STS & POL are deactivated by blood proteins 1,2 Conner et al 3 found detergent sclerosants are also deactivated by circulating blood cells. This deactivating effect is above and beyond the neutralizing effects of plasma proteins and contributes to the overall neutralizing effect of blood. At high enough concentrations, surfactants solubilise cell membranes resulting in cell lysis. In Vitro study: endothelial cell lysis at STS.25% and POL 0.4% 2 Watkns. European Journal of Vascular & Endovascular Surgery 2011;41(4): Parsi et al. Eur J Vasc Endovasc Surg (2008) 36, 216e223.
18 Samples of whole blood, platelet-rich plasma, and isolated leukocytes were incubated with various concentrations of STS or POL and added to human umbilical vein endothelial cells Detergent sclerosant activity was decreased in WB when compared with plasma and saline controls Detergent sclerosants are consumed and deactivated by circulating blood cells. This deactivating effect is above and beyond the neutralizing effects of plasma proteins and contributes to the overall neutralizing effect of blood. Connor et al. Eur J Vasc Endovasc Surg (2015) 49, 426e431
19 Liquid Detergent Sclerosants & Endothelial Cell Death Cell cultures of bovine aortic endothelial cells Continuous exposure to varying concentrations of Pol ( %) and STS ( %) Fluorescence imaging every 2-6 seconds for up to 60 minutes to assess: Intracellular calcium Nitric oxide Cell death Kobayashi et. al. Derm Surg 2006;32(12):
20 Liquid Detergent Sclerosants & Endothelial Cell Death Time to response for all markers was inversely related to sclerosant concentration STS 0.5% STS 0.1% STS 0.02% STS 0.005% 15 seconds to cell death 3.5 minutes to cell death 15 minutes to cell death no cell death Appeared to be sequential activation of Calcium-dependent pathways Nitric oxide production Followed by rapid progression to cell death
21 French POL Study 12 physicians- Data on 1,605 patients included in the French registry were reviewed with a maximum followup of 60 months, covering 3,357 patient years. Most of the sessions were performed with sclerosants in foamed formulation (n = 4,403); the rest (n = 2,041) was performed with liquid sclerosants.
22 French Study
23 Australian POL study 98 physicians, limbs, results at 2 years 65 Investigators utilized polidocanol and compared it to their previous use of other sclerosants % for spider veins 85% felt POL superior to STS 90% felt fewer complications Conrad et al. Derm Surg 1995;25:334-6.
24 Goldman RCT 129 pts w/o related underlying reflux Spider veins, reticular veins, varicose veins Spiders:.25% STS or.5% POL 3 Independent blinded photo reviewers at 4 and 16 wks Both groups average 70% improvement Similar side effect rate
25
26 EASI Study Double blind, randomized prospective study Spider veins (n=160) 0.5% Pol 1% STS placebo Reticular veins (n=156) 1% Pol 1% STS placebo Rabe et al. Phlebology Jun;25(3):124-31s
27 Treatment Success Rates Treatment Success * Rated by blinded panel Defined as grade 4 0r 5 (good or complete success) No difference between Pol and STS *Treatment success was rated on a 5-point scale: 1 = worse than before 2 = same as before 3 = moderate improvement 4 = good improvement 5 = complete treatment success
28 Patient Satisfaction Patients Satisfied/Very Satisfied 100% 80% 60% 40% 20% Patient Satisfaction rated on 1-5 scale (% reflects patients satisfied or very 87% satisfied) 84% 64% 14% 63% 16% Asclera (0.5% or 1%) STS (1%) Placebo (0.9% isotonic saline) 0% 12 weeks 26 weeks P< for all comparisons
29 Actually, Too POL high concentration a (0.5/1.0 %) also too high of STS (1%) Complications 80% 70% 60% 50% 40% 30% STS POL 20% 10% 0% Pigmentation Necrosis Matting
30 Complications 80% 70% 60% 50% Used too high a concentration of STS 40% 30% STS POL 20% 10% 0% Pigmentation Necrosis Matting Rabe et al. Phlebology Jun;25(3):124-31
31 Spider vein: HS vs POL Non-randomized study in 113 consecutive patients HS POL.5 % POL 1 % Pigmentation 10.8% 20% 30.7% Matting 13 % 10% 33% POL concentration probably too high Weiss and Weiss. Derm Surg 1990, 16(9):800-4.
32 Liquid vs Foam Spider veins: Higher incidence pigmentation, ulceration1 French POL Study 2 : We recommend the use of liquid polidocanol for treatment of spider, reticular, and small varicose veins Liquid treatment of choice in C1 patients 3 1. Kern et al. Derm Surg Mar;30(3): Guex et al. Derm Surg 2010;36:S2: Rabe et al. European guidelines. Phlebology,
33 Sclerosant: Liquid vs Foam RCT: 75 pts (69 women) served as their own control Reticular or post-op varices 1 session: POL liquid or foam Concentration adjusted based on vein size [Foam] 50% lower than liquid Eur J Vasc Endovasc Surg Jan;31(1):101-7.
34 Sclerosant Concentration The key is to deliver a minimum sclerosant volume & concentration to irreversibly damage the endothelium & cause complete sclerosis, without collateral damage. Spider Veins Reticular Veins Varicose Veins HS % n/a n/a D/ S FS (25%/10%) n/a n/a G 72% n/a n/a Pol.25-.5%.5-1% 1-3% STS.1 -.2%.2 -.5%.33 3%
35 Cost of FDA-Approved Agents Sotradecol Cost/mL Asclera Cost/mL 1% $57.5% $10 3% $63 1% $11.15% $ % $3.33
36
37 Compounded Sclerosants 1% Polidocanol concentrations ranged 1-3%, and impurities found 1 STS 3% concentrations ranged 2.59%-3.39% and carbitol present in samples from all three sources (0.33%-4.18%) 2 Weiss et al. Dermatol Surg Jun;37(6): Goldman. Dermatol Surg Dec;30(12 Pt 1):
38 Compounding: Ask Yourself Is an FDA-approved version available? Do you inform your patients you re using a compounded version as a substitute for an FDA-approved medication? Why are you using a compounded product when an FDA-approved version exists? If compounded drug determined to be the cause of a negative, preventable outcome, the physician may be liable for selecting the compounded drug Think New England Compounding Center
39
[Kreussler Studies] FDA. multicenter GCP. controlled. randomized. prospective. blinded SUMMARY OF PIVOTAL STUDIES ON SCLEROTHERAPY OF VARICOSE VEINS
[Kreussler Studies] SUMMARY OF PIVOTAL STUDIES ON SCLEROTHERAPY OF VARICOSE VEINS FDA randomized controlled GCP blinded prospective multicenter [Sclerotherapy of Varices] Healthy legs with microfoam Chemische
More informationDOSAGE FORMS AND STRENGTHS
HIGHLIGHTS OF PRESCRIBING INFORMATION: These highlights do not include all the information needed to use Asclera Injection safely and effectively. See full prescribing information for Asclera. Asclera
More informationClinical comparison of sodium tetradecyl sulfate 0.25% versus polidocanol 0.75% in sclerotherapy of lower extremity telangiectasia
ORIGINAL ARTICLE Clinical comparison of sodium tetradecyl sulfate 0.25% versus polidocanol 0.75% in sclerotherapy of lower extremity telangiectasia Wafaa M Ramadan, MD, Khaled H El-Hoshy, MD, Dalia M Shaaban,
More informationVisual Sclerotherapy. 1:24-1:36 Now 10 minutes flying along. Nick Morrison, MD, FACPh, FACS President, International Union of Phlebology
1:24-1:36 Now 10 minutes flying along Visual Sclerotherapy Nick Morrison, MD, FACPh, FACS President, International Union of Phlebology Sedona, Arizona Canyon de Chelly, Airzona Disclosures Educational
More informationWhich place for liquid sclerotherapy? Eberhard Rabe Department of Dermatology University of Bonn Germany
Which place for liquid sclerotherapy? Eberhard Rabe Department of Dermatology University of Bonn Germany Liquid Foam or GSV, foam / liquid sclerosant n diameter[mm] Follow up effectivity Hamel Desnos 2003
More informationDisclosure. Lowell Kabnick, M.D., FACS, FACPh. I disclose the following financial relationship(s):
Disclosure Lowell Kabnick, M.D., FACS, FACPh I disclose the following financial relationship(s): Research Grant: BTG; Ownership Interest: AngioDynamics, Vascular Insights; Consultant/Advisory Board: AngioDynamics,
More informationAVOIDING COMPLICATIONS IN LIQUID SCLEROTHERAPY. Steven E. Zimmet, MD RPVI RVT FACPh
AVOIDING COMPLICATIONS IN LIQUID SCLEROTHERAPY Steven E. Zimmet, MD RPVI RVT FACPh Disclosures No conflicts of interest Overview Hyperpigmentation Matting Ulceration Thrombosis Anaphylaxis Neurological
More informationTreatment of telangiectasias by. foam sclerotherapy? under. ultrasound guidance. How to ensure the success of. 10 rules to respect
How to ensure the success of foam sclerotherapy? under 10 rules to respect Treatment of telangiectasias by ultrasound guidance Claudine Claudine Hamel-Desnos MD Hôpital Privé Caen- Saint France Martin
More informationSclerosing Agents: Tips & Tricks Session: Liquid Embolics
Sclerosing Agents: Tips & Tricks Session: Liquid Embolics Jeffrey S. Pollak, M.D. Robert I. White, Jr., M.D. Professor of Interventional Radiology Yale University School of Medicine Department of Radiology
More informationEpidemiology: Prevalence
Epidemiology: Prevalence More than 30 million Americans suffer from varicose veins or a more serious form of venous disease called Chronic Venous Insufficiency (CVI). 1 Of the over 30 million Americans
More informationAdditional Information S-55
Additional Information S-55 Network providers are encouraged, but not required to participate in the on-line American Venous Forum Registry (AVR) - The First National Registry for the Treatment of Varicose
More informationEvaluation of lidocaine as an analgesic when added to hypertonic saline for sclerotherapy
Evaluation of lidocaine as an analgesic when added to hypertonic saline for sclerotherapy Rizwan H. Bukhari, MD, Joann M. Lohr, MD, Douglas S. Paget, MD, Andrew T. Hearn, MD, and Robert D. Cranley, MD,
More informationDESCRIPTION Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. The structural formula is as follows:
SOTRADECOL- tetradecyl hydrogen sulfate (ester) injection, solution Mylan Ins titutional LLC ---------- SOTRADECOL (Sodium Tetradecyl Sulfate Injection) 1% 20 mg/2 ml (10 mg/ml) and 3% 60 mg/2 ml (30 mg/ml)
More informationpressure of compression stockings matters (clinical importance of pressure)
Classification of Compression Stockings ICC Meeting, Copenhagen, May 17, 2013. pressure of compression stockings matters (clinical importance of pressure) Giovanni Mosti; Lucca, Italy disclosure no conflict
More informationVaricose Veins What Are They? Sclerotherapy in the Treatment of Venous Disease Zachary C. Schmittling, MD, FACS May 4, 2018
Sclerotherapy in the Treatment of Venous Disease Zachary C. Schmittling, MD, FACS May 4, 2018 Sclerotherapy for Venous Disease: Overview 1 in 5 Americans Approximately 25% of women have some type of lower
More informationPROF S.R.SUBRAMMANIYAN INSTITUTE OF VASCULAR SURGERY MADRAS MEDICAL COLLEGE
PROF S.R.SUBRAMMANIYAN INSTITUTE OF VASCULAR SURGERY MADRAS MEDICAL COLLEGE VARICOSE VEINS OF SUPERFICIAL VENOUS SYSTEM OF LOWER LIMBS A SYMPTOM NOT A DISEASE INITIAL,MILD CASES and severe cases with contraindication
More informationInterventional Treatment VTE: Radiologic Approach
Interventional Treatment VTE: Radiologic Approach Hae Giu Lee, MD Professor, Dept of Radiology Seoul St. Mary s Hospital The Catholic University of Korea Introduction Incidence High incidence: 250,000-1,000,000/year
More informationGraduated compression stockings are universally
Efficacy of Graduated Compression Stockings for an Additional 3 Weeks after Sclerotherapy Treatment of Reticular and Telangiectatic Leg Veins PAVAN K. NOOTHETI, MD, KRISTIAN M. CADAG, BS, ANGELA MAGPANTAY,
More informationInfluence of Warfarin on the Success of Endovenous Laser Ablation (EVLA) of the Great Saphenous Vein (GSV)
Eur J Vasc Endovasc Surg (2009) 38, 506e510 Influence of Warfarin on the Success of Endovenous Laser Ablation (EVLA) of the Great Saphenous Vein (GSV) N.S. Theivacumar, M.J. Gough* Leeds Vascular Institute,
More informationSelf-assembled nanostructures soft and hard matter
Hands-On Nano-Technology course Nano-Science Center University of Copenhagen Self-assembled nanostructures soft and hard matter One-day workshop, August 12, 2004 Division of Physical Chemistry 1, Center
More informationThermal Techniques: Outcomes and Complications
Thermal Techniques: Outcomes and Complications Meet The Experts: Thermal and Non-Thermal Ablation Techniques Joseph D. Raffetto MD VA Boston HCS, West Roxbury, MA, Harvard Medical School, Boston, MA; Brigham
More informationSurfactants. The Basic Theory. Surfactants (or surface active agents ): are organic compounds with at least one lyophilic. Paints and Adhesives
Surfactants Surfactants (or surface active agents ): are organic compounds with at least one lyophilic ( solvent-loving ) group and one lyophobic ( solvent-fearing ) group in the molecule. In the simplest
More informationExpanding Your Vein Business Terri Morrison, RN, B.S., CEO Morrison Vein Institute Scottsdale/Tempe Arizona
Expanding Your Vein Business Terri Morrison, RN, B.S., CEO Morrison Vein Institute Scottsdale/Tempe Arizona March 8, 2011 Varicose Vi Vein Market Approximately 40% of the US population has venous disease;
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 June 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 June 2012 Examination of the dossier for the proprietary medicinal products included for a period of 5 years, renewable
More informationLe varici recidive Recurrent varices: how to manage them?
Le varici recidive Recurrent varices: how to manage them? Marianne De Maeseneer MD PhD, Vascular Surgeon Department of Dermatology, Rotterdam, Netherlands & Faculty of Medicine and Health Sciences University
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Fibrovein 3%, 1%, 0.5% and 0.2% Solution for Injection Sodium tetradecyl sulphate
PACKAGE LEAFLET: INFORMATION FOR THE USER Fibrovein 3%, 1%, 0.5% and 0.2% Solution for Injection Sodium tetradecyl sulphate Read all of this leaflet carefully before you start using this medicine. Keep
More informationBIOPHYSICS II. By Prof. Xiang Yang Liu Department of Physics,
BIOPHYSICS II By Prof. Xiang Yang Liu Department of Physics, NUS 1 Hydrogen bond and the stability of macromolecular structure Membrane Model Amphiphilic molecule self-assembly at the surface and din the
More informationMechanochemical endovenous ablation in the treatment of varicose veins van Eekeren, Ramon
University of Groningen Mechanochemical endovenous ablation in the treatment of varicose veins van Eekeren, Ramon DOI: 10.1053/j.semvascsurg.2015.02.002 10.1016/j.ejvs.2012.12.004 10.1016/j.jvsv.2014.01.001
More informationChronic Venous Insufficiency Compression and Beyond
Disclosure of Conflict of Interest Chronic Venous Insufficiency Compression and Beyond Shawn Amyot, MD, CCFP Fellow of the Canadian Society of Phlebology Ottawa Vein Centre I do not have relevant financial
More informationLASERS: CAN THEY TREAT SPIDER VEINS? Steven E. Zimmet, MD
LASERS: CAN THEY TREAT SPIDER VEINS? Steven E. Zimmet, MD No conflicts of interest DISCLOSURES YES! WHY USE LASERS FOR LEG VEINS? Patient s Perception Less Painful Newer technology Must be better Needle
More informationPHLEBOLOGY. Venous Insufficiency. Presentation Use Information
Disclosure of Conflict of Interest THE BASICS OF VENOUS INSUFFICIENCY: What You Should Know. An Introductory Lecture Donald Ives, MD, RVT, RPVI Board Certified Family Physician Diplomate of the American
More informationLast literature review version 19.3: Fri Sep 30 00:00:00 GMT 2011 This topic last updated: Thu Sep 30 00:00:00 GMT 2010 (More)
19.3 Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins Authors Deborah L Greenberg, MD, FACP Sherry Scovell, MD, FACS Section Editors John F Eidt, MD Joseph L Mills, Sr,
More informationSegmental GSV reflux
Segmental GSV reflux History of presentation A 43 year old female presented with right lower extremity varicose veins and swelling. She had symptoms of aching, heaviness and tiredness in the right leg.
More informationColloid chemistry. Lecture 10: Surfactants
Colloid chemistry Lecture 10: Surfactants Applications of surfactants: cleaning/detergents (40%); textiles; cosmetics; pharmacy; paint; food; etc. Etymology Surfactant micelles surfactant molecule spherical
More informationLove your legs again Varicose Veins
Love your legs again Varicose Veins Veins are the vessels that return blood to the heart once it has circulated through the body (as opposed to arteries, which carry oxygen-rich blood from the heart to
More informationAging hands are characterized by prominent
Foam Sclerotherapy for Reticular Veins of the Dorsal Hands: A Retrospective Review Anne Marie Tremaine, MD,* Daniel P. Friedmann, MD, and Mitchel P. Goldman, MD BACKGROUND Despite being the gold standard
More informationCriteria For Medicare Members. Kaiser Foundation Health Plan of Washington
Clinical Review Criteria Treatment of Varicose Veins Radiofrequency Catheter Closure Sclerotherapy Surgical Stripping Trivex System for Outpatient Varicose Vein Surgery VenaSeal Closure System VNUS Closure
More informationConflict of Interest. None
Conflict of Interest None American Venous Forum Guidelines on Superficial Venous Disease TOP 10 GUIDELINES 10. We recommend using the CEAP classification to describe chronic venous disorders. (GRADE 1B)
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 June 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 June 2012 AETOXISCLEROL TAMPONNE 0.5% (10 mg/2 ml) IV B/5 x 2 ml vials (CIP code: 347 752-4) AETOXISCLEROL TAMPONNE
More informationVenous Disease and Leg Ulcers. Edward G Mackay MD St. Petersburg, FL NCVH 2015 Orlando, FL
Venous Disease and Leg Ulcers Edward G Mackay MD St. Petersburg, FL NCVH 2015 Orlando, FL Disclosures Stocks Endoshape Sapheon Medical Advisory Board BTG, Boston Scientific Venous Leg Ulcer Most common
More informationV I U R E V I E W. T h e O f f i c i a l J o u r n a l o f V e n o u s I n s u f f i c i e n c y U n i v e r s i t y
C o m p l i m e n t s o f S a n j i v L a k h a n p a l, M D, J a i m e M a r q u e z, M D, J e r r i l y n J u t t o n, M D, K e l l y O ' D o n n e l l, M D, R a j i v J h a v e r i, M D, L u i s A.
More informationTREATMENT OPTIONS FOR CHRONIC VENOUS INSUFFICIENCY
TREATMENT OPTIONS FOR CHRONIC VENOUS INSUFFICIENCY TL LUK Consultant Vascular Surgeon Sarawak General Hospital HKL Vascular Conference 19/06/2013 PREVALENCE OF LOWER LIMB VENOUS DISEASE Affects half of
More informationPart IV Antithrombotics, Anticoagulants and Fibrinolytics
Part IV Antithrombotics, Anticoagulants and Fibrinolytics "The meaning of good and bad, of better and worse, is simply helping or hurting" Emerson Chapter 16: Blood Coagulation and Fibrinolytic System
More informationSetting The setting was an outpatient clinic. The economic study was carried out in the UK.
Ultrasound-guided foam sclerotherapy combined with sapheno-femoral ligation compared to surgical treatment of varicose veins: early results of a randomised controlled trial Bountouroglou D G, Azzam M,
More informationMedicare C/D Medical Coverage Policy
Varicose Vein Treatment Medicare C/D Medical Coverage Policy Origination Date: June 1, 1993 Review Date: February 15, 2017 Next Review: February, 2019 DESCRIPTION OF PROCEDURE OR SERVICE Varicose veins
More informationOriginal Article Intervention
Original Article Intervention http://dx.doi.org/10.3348/kjr.2014.15.4.481 pissn 1229-6929 eissn 2005-8330 Korean J Radiol 2014;15(4):481-487 Fluoroscopy-Guided Endovenous Sclerotherapy Using a Microcatheter
More informationISSN X (Print)
Scholars Journal of Applied Medical Sciences (SJAMS) Sch. J. App. Med. Sci., 2015; 3(8B):2841-2846 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources)
More informationAppendix 1 to Direct Vision Sclerotherapy AUSTRALASIAN COLLEGE OF PHLEBOLOGY CLINICAL PROCEDURES. CP Direct Vision Sclerotherapy Clinical procedure
Appendix 1 to Direct Vision Sclerotherapy AUSTRALASIAN COLLEGE OF PHLEBOLOGY CLINICAL PROCEDURES CP Direct Vision Sclerotherapy Clinical procedure 1 PURPOSE This procedure summarises the actions required
More informationRecurrent Varicose Veins We All See Them
We All See Them November 4, 2017 Austin, TX Arlington Heights, IL No conflicts Terminology REVAS REcurrent Varices After Surgery PREVAIT PREsence of Varices After Interventional Treatment Recurrent varices
More informationCONTRAINDICATIONS Known allergy to polidocanol (4) Acute thromboembolic disease (4)
HIGHLIGHTS F PRESCRIBING INFRMATIN These highlights do not include all the information needed to use Varithena safely and effectively. See Full Prescribing Information for VARITHENA. VARITHENA (polidocanol
More informationWhat are blood clots?
What are blood clots? Dr Matthew Fay GP Principal The Willows Medical Practice- Queensbury GPwSI and Co-Founder Westcliffe Cardiology Service GP Partner Westcliffe Medical Group Created 5/31/18 Dr. Matthew
More informationSclerotherapy Complications and Contra-Indications
Sclerotherapy Complications and Contra-Indications Dr Paul Thibault Phlebologist Newcastle NSW Sclerotherapy Complications and Contraindications Not everything that needs to be known can be taught Sclerotherapy
More informationAir versus Physiological Gas for Ultrasound Guided Foam Sclerotherapy Treatment of Varicose Veins
Eur J Vasc Endovasc Surg (2011) 42, 115e119 Air versus Physiological Gas for Ultrasound Guided Foam Sclerotherapy Treatment of Varicose Veins T. Beckitt*, A. Elstone, S. Ashley Vascular Surgical Unit,
More informationAmbulatory Phlebectomy & Sclerotherapy. Dr. S. Kundu Medical Director The Vein Institute of Toronto
Ambulatory Phlebectomy & Sclerotherapy Dr. S. Kundu Medical Director The Vein Institute of Toronto 1 Disclosures Consultant: Bard Canada Boston Scientific Canada Edwards Life Sciences Baylis Canada Sigmacon
More informationBear: Neuroscience: Exploring the Brain 3e
Bear: Neuroscience: Exploring the Brain 3e Chapter 03: The Neuronal Membrane at Rest Introduction Action potential in the nervous system Action potential vs. resting potential Slide 1 Slide 2 Cytosolic
More informationVaricose Veins are a Symptom of Vein Disease. Now you can treat the source of your varicose veins with non-surgical endovenous laser treatment.
Varicose Veins are a Symptom of Vein Disease. Now you can treat the source of your varicose veins with non-surgical endovenous laser treatment. Approximately 1 in 5 adult Americans suffer from superficial
More informationFor the use of only Oncologist or a Cancer Hospital or a laboratory Doxorubicin Hydrochloride Liposome Injection 2 mg/ml KEMODOXA
For the use of only Oncologist or a Cancer Hospital or a laboratory Doxorubicin Hydrochloride Liposome Injection 2 mg/ml KEMODOXA COMPOSITION Each ml contains: Doxorubicin Hydrochloride IP...2 mg Water
More informationManagement of Superficial Reflux: Which option, when? Kathleen Gibson, MD Lake Washington Vascular Surgeons Bellevue, WA
Management of Superficial Reflux: Which option, when? Kathleen Gibson, MD Lake Washington Vascular Surgeons Bellevue, WA DISCLOSURES Kathleen Gibson, MD Consultant/Advisory Board: BTG, Medtronic Speakers
More informationPerforators: When to Treat and How Best to Do It? Eric Hager, MD September 10, 2015
Perforators: When to Treat and How Best to Do It? Eric Hager, MD September 10, 2015 Anatomy of Perforating veins Cadaveric studies 1 have shown >60 vein perforating veins from superficial to deep Normal
More informationInteractions between Bisphosphate. Geminis and Sodium Lauryl Ether
Chapter 5 Interactions between Bisphosphate Geminis and Sodium Lauryl Ether Sulphate 110 5.1 Introduction The physiochemical and surface active properties of mixed surfactants are of more interest and
More informationPaper 4. Biomolecules and their interactions Module 22: Aggregates of lipids: micelles, liposomes and their applications OBJECTIVE
Paper 4. Biomolecules and their interactions Module 22: Aggregates of lipids: micelles, liposomes and their applications OBJECTIVE The main aim of this module is to introduce the students to the types
More informationAre there differences in guidelines for management of CVD between Europe and the US? Bo Eklöf, MD, PhD Lund University Sweden
Are there differences in guidelines for management of CVD between Europe and the US? Bo Eklöf, MD, PhD Lund University Sweden Disclosures No disclosures Five sources for comparison SVS/AVF US guidelines
More informationLessons & Perspectives: What is the role of Cryoplasty in SFA Intervention?
Lessons & Perspectives: What is the role of Cryoplasty in SFA Intervention? Michael Wholey, MD, MBA San Antonio, TX USA 19/06/2009 at 09:35 during 4mn as a Speaker Session: Improving Femoral Artery Recanalization
More informationMEDICAL POLICY SUBJECT: VARICOSITIES, TREATMENT ALTERNATIVES TO VEIN STRIPPING AND LIGATION. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY PAGE: 1 OF: 9 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationFor topical use only. Not for oral, ophthalmic, or intravaginal use.
DESOXIMETASONE Ointment USP, 0.25% For topical use only. Not for oral, ophthalmic, or intravaginal use. Rx only DESCRIPTION Desoximetasone ointment USP, 0.25% contains the active synthetic corticosteroid
More informationDeep Venous Pathology. Eberhard Rabe Department of Dermatology University of Bonn Germany
Deep Venous Pathology Eberhard Rabe Department of Dermatology University of Bonn Germany Disclosures None for this presentation Consultant: Sigvaris, EUROCOM Speakers bureau: Bayer Vital, Aspen, Boehringer,
More informationLiquid crystals; biological and artificial membranes
Liquid crystals; biological and artificial membranes Dr. István Voszka Liquid crystals: Intermediate state between liquids and crystalline solids anisotropic liquids. (anisotropy = the physical properties
More informationPhysical Pharmacy. Interfacial phenomena. Khalid T Maaroof MSc. Pharmaceutical sciences School of pharmacy Pharmaceutics department
Physical Pharmacy Interfacial phenomena Khalid T Maaroof MSc. Pharmaceutical sciences School of pharmacy Pharmaceutics department 1 Introduction The boundary between two phases is generally described as
More informationVein & Body Specialists at The Bellevue Hospital Spider Vein and Varicose Vein Treatments
1 Vein & Body Specialists at The Bellevue Hospital Spider Vein and Varicose Vein Treatments What are spider veins? Spider veins are dilated, small blood vessels that have a red or bluish color. They appear
More informationWHAT ABOUT FOAM SCLEROTHERAPY IN REVAS? Dr O CRETON Ste FOY LES LYON
WHAT ABOUT FOAM SCLEROTHERAPY IN REVAS? Dr O CRETON Ste FOY LES LYON Disclosure of Interest I have the following potential conflicts of interest to report: Consulting: Medtronic WHAT ABOUT REVAS? Source
More informationDurability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2)
From the American Venous Forum Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2) Kenneth L. Todd III, MD, a and David I. Wright, MD,
More informationPriorities Forum Statement
Priorities Forum Statement Number 9 Subject Varicose Vein Surgery Date of decision September 2014 Date refreshed March 2017 Date of review September 2018 Relevant OPCS codes: L841-46, L848-49, L851-53,
More informationSAVE LIMBS SAVE LIVES! Endovenous Ablation for Chronic Wounds
SAVE LIMBS SAVE LIVES! Endovenous Ablation for Chronic Wounds Frank J. Tursi, DPM, FACFS Clinical Associate Professor, University of Pennsylvania/Presbyterian Foot and Ankle Consultant, Philadelphia Flyers,
More informationCell membrane & Transport. Dr. Ali Ebneshahidi Ebneshahidi
Cell membrane & Transport Dr. Ali Ebneshahidi Cell Membrane To enclose organelles and other contents in cytoplasm. To protect the cell. To allow substances into and out of the cell. To have metabolic reactions
More informationOHTAC Recommendation. Endovascular Laser Treatment for Varicose Veins. Presented to the Ontario Health Technology Advisory Committee in November 2009
OHTAC Recommendation Endovascular Laser Treatment for Varicose Veins Presented to the Ontario Health Technology Advisory Committee in November 2009 April 2010 Issue Background The Ontario Health Technology
More informationNon-Saphenous Vein Treatments. Jessica Ochs PA-C Albert Vein Institute Colorado Springs and Lone Tree, CO
Non-Saphenous Vein Treatments Jessica Ochs PA-C Albert Vein Institute Colorado Springs and Lone Tree, CO I have no financial disclosures Types of Veins Treated Perforator Veins Tributary Veins Varicose
More informationAcoustic Pulse Thrombolysis Treatment
Acoustic Pulse Thrombolysis Treatment BTGVascular.com SETTING THE STANDARD FOR VASCULAR THERAPIES Quickly & safely dissolve thrombus with the EKOS System. The Acoustic Pulse Difference Acoustic Pulse Thrombolysis
More informationMechanisms of Anionic Detergent-Induced Hemolysis
Gen Physiol Biophys (1998), 17, 265 270 265 Mechanisms of Anionic Detergent-Induced Hemolysis E CHERNITSKY AND O SENKOVICH Institute of Photobiology, National Academy of Sciences of Belarus, Minsk, Belarus
More informationCONTRAINDICATIONS Known allergy to polidocanol (4) Acute thromboembolic disease (4)
HIGHLIGHTS F PRESCRIBING INFRMATIN These highlights do not include all the information needed to use VARITHENA safely and effectively. See Full Prescribing Information for VARITHENA. VARITHENA (polidocanol
More informationBiology Chapter 2 Review
Biology Chapter 2 Review Vocabulary: Define the following words on a separate piece of paper. Element Compound Ion Ionic Bond Covalent Bond Molecule Hydrogen Bon Cohesion Adhesion Solution Solute Solvent
More informationFoam Sclerotherapy of the Saphenous Veins: Randomised Controlled Trial with or without Compression
Eur J Vasc Endovasc Surg (21) 39, 5e57 Foam Sclerotherapy of the Saphenous Veins: Randomised Controlled Trial with or without Compression C.M. Hamel-Desnos a, *, B.J. Guias b, P.R. Desnos c, A. Mesgard
More information*Sections or subsections omitted from the full prescribing information are not listed.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GIAPREZA TM safely and effectively. See full prescribing information for GIAPREZA. GIAPREZA (angiotensin
More informationUNDERSTANDING VEIN DISEASE. UC EN - For use in the U.S. only
UNDERSTANDING VEIN DISEASE UC201706537 EN - For use in the U.S. only Do you need to sit down during your work day because your legs ache and/or swell? Do you miss out on doing the activities you love because
More informationWhat is the optimal time window for treating deep venous thrombosis? Acute vs subacute vs chronic
What is the optimal time window for treating deep venous thrombosis? Acute vs subacute vs chronic Peter A. Schneider, MD Chief of Vascular Therapy Kaiser Foundation Hospital Honolulu, Hawaii Disclosure
More informationPhlebectomy vs sclerotherapy ALESSANDRO FRULLINI MD FLORENCE - ITALY
Phlebectomy vs sclerotherapy ALESSANDRO FRULLINI MD FLORENCE - ITALY DISCLOSURE Consultant for: GloriaMed Personal background General and vascular surgeon More than 3500 stripping performed 33 years of
More informationPhlebogriffe a new device for mechanochemical ablation of incompetent saphenous veins: a pilot study
Phlebogriffe a new device for mechanochemical ablation of incompetent saphenous veins: a pilot study Piotr Ciostek 1, Marcin Kowalski 1, Witold Woźniak 1, Tomasz Miłek 1, Piotr Myrcha 1, Bartosz Migda
More informationELSPAR (asparaginase) For injection, intravenous or intramuscular Initial U.S. Approval: 1978
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Elspar safely and effectively. See full prescribing information for Elspar. ELSPAR (asparaginase)
More informationThe Society for Vascular Surgery Patient Safety Organization: Use of A Quality Registry for Practice Improvement
The Society for Vascular Surgery Patient Safety Organization: Use of A Quality Registry for Practice Improvement Georgia Vascular Society Adam W. Beck, MD, FACS September 9, 2017 Disclosures No relevant
More informationBlocking the Saphenofemoral Junction During Ultrasound-Guided Foam Sclerotherapy e Assessment of a Presumed Safety-measure Procedure
Eur J Vasc Endovasc Surg (2010) 40, 772e776 Blocking the Saphenofemoral Junction During Ultrasound-Guided Foam Sclerotherapy e Assessment of a Presumed Safety-measure Procedure R.P.M. Ceulen a,d, *, E.A.
More informationWHITE PAPERS PRESENTATION VIDEO DOCUMENTATION EXPERIMENT WO NDCLOT. The WoundClot Principals for Effective Bleeding Control PRESENTATION
WHITE PAPERS PRESENTATION VIDEO DOCUMENTATION EXPERIMENT ARTICLES OUR STUDY BLEEDING CONTROL 5 POINT MODEL WO NDCLOT The WoundClot Principals for Effective Bleeding Control PRESENTATION Harnessing SCIENCE
More informationTreatment of Varicose Veins
Treatment of Varicose Veins Policy Number: Original Effective Date: MM.06.016 04/15/2005 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration 09/28/2018 Section: Surgery Place(s) of
More informationA Novel Sulfonated Alkyl Ester Surfactant to Reduce Oil-Water Interfacial Tensions in Wide Range Salinity with Monovalent and Divalent Ions
Modern Applied Science; Vol. 10, No. 1; 2016 ISSN 1913-1844 E-ISSN 1913-1852 Published by Canadian Center of Science and Education A Novel Sulfonated Alkyl Ester Surfactant to Reduce Oil-Water Interfacial
More informationBranch of medicine that deals with blood, its formation and disorders is called. Three main functions of cardiovascular system are,, and.
Chapter 19 The Blood Human body must maintain a balance called. Body fluid inside the cells is called fluid; that outside is called or fluid. Two major fluid networks that help in connecting cells are
More informationThe Management of Stasis Dermatitis and Chronic Venous Insufficiency in Patients Refractory to Conservative Therapies
Article The Management of Stasis Dermatitis and Chronic Venous Insufficiency in Patients Refractory to Conservative Therapies Kareem Halim, 1,2, * Mark J. McElroy, 1 and John A. Lewis 3 1 Havard Medical
More informationGlossary For TheFatNurse s For All Ages Series Adipocytes, also known as lipocytes and fat cells, are the cells that primarily compose adipose tissue, specialized in storing energy as fat. Apolipoprotein
More informationPROVIDER POLICIES & PROCEDURES
PROVIDER POLICIES & PROCEDURES TREATMENT OF VARICOSE VEINS OF THE LOWER EXTREMITIES STAB PHLEBECTOMY AND SCLEROTHERAPY TREATMENT The primary purpose of this document is to assist providers enrolled in
More informationSurfactant. An Introduction to Water Tension and Alveoli Structure and the necessity for Septal Cell Surfactant. By Noel Ways
Surfactant An Introduction to Water Tension and Alveoli Structure and the necessity for Septal Cell Surfactant By Noel Ways Gas exchange occurs over the moist surface of the alveoli, but water (H 2 O)
More informationFish Skin Grafts Promote Superior Cell Ingrowth Compared to Amnion Allografts, Human Cadaver Skin and Mammalian Extracellular Matrix (ECM)
Fish Skin Grafts Promote Superior Cell Ingrowth Compared to Amnion Allografts, Human Cadaver Skin and Mammalian Extracellular Matrix (ECM) Christopher L. Winters, DPM American Health Network Indianapolis,
More informationMulti-Application Platform. Summary of Peer-reviewed Articles for Various Clinical Indications April 2016
Multi-Application Platform Summary of Peer-reviewed Articles for Various Clinical Indications April 2016 Various Clinical Indications Atrophic acne scars and acne Photo-aged skin, pigmentation & hyperpigmentation
More information